Welcome to our dedicated page for Virios Therapeutics news (Ticker: VIRI), a resource for investors and traders seeking the latest updates and insights on Virios Therapeutics stock.
Virios Therapeutics, Inc. (VIRI) is a clinical-stage biotechnology company advancing novel therapies for unmet medical needs through rigorous research and strategic collaborations. This page serves as your centralized source for official company announcements and developments.
Access timely updates on clinical trial progress, regulatory milestones, and partnership agreements. Investors and researchers will find essential information about therapeutic pipeline advancements, financial disclosures, and scientific publications. All content is verified through primary sources to ensure accuracy.
Key updates include trial phase results, intellectual property developments, and executive leadership announcements. Bookmark this page to stay informed about Virios Therapeutics' contributions to biopharmaceutical innovation without needing to track multiple channels.
Virios Therapeutics (Nasdaq: VIRI) announced that CEO Greg Duncan will present a company overview at the Benzinga Global Small Cap Conference on May 14, 2021, at 11:55 a.m. ET. The presentation will highlight the need for innovative treatments for fibromyalgia (FM) and explore the potential of IMC-1, a novel antiviral approach that showed promise in a Phase 2 clinical trial. IMC-1 represents a combination of famciclovir and celecoxib aimed at suppressing HSV-1 replication, targeting symptoms associated with FM. For more information, visit the company’s website.
Virios Therapeutics (Nasdaq: VIRI) is set to announce its Q1 2021 financial results on May 13, 2021, prior to market opening. A conference call will follow at 8:30 a.m. ET for discussion and updates. The company specializes in dual mechanism antiviral therapies, primarily targeting conditions linked to herpes simplex virus-1, including fibromyalgia. Virios’s lead candidate, IMC-1, has shown promise in a Phase 2a trial and is currently undergoing a Phase 2b trial, FORTRESS, with FDA fast track designation.
Virios Therapeutics (Nasdaq: VIRI) announced that its Chairman and CEO, Greg Duncan, will be featured on The RedChip Money Report, airing on Bloomberg Network on April 17, 2021, at 7 p.m. Eastern Time. The company is focused on developing novel antiviral therapies for diseases linked to immune responses triggered by viruses. Their lead candidate, IMC-1, is a fixed-dose combination therapy targeting herpes simplex virus-1, showing promising results in Phase 2 trials for fibromyalgia and currently undergoing a Phase 2B trial. The FDA has granted IMC-1 fast track designation.
Virios Therapeutics (Nasdaq: VIRI) announced its participation in the Needham Virtual Healthcare Conference on April 14, 2021, at 4:30 p.m. ET. Greg Duncan, CEO, and R. Michael Gendreau, Chief Medical Officer, will discuss the company’s novel antiviral approach to fibromyalgia (FM) and present promising Phase 2 clinical trial results for their lead candidate, IMC-1. The company is focused on developing therapies for diseases linked to viral immune responses. A link to the live and archived presentation will be available on their website.
Virios Therapeutics, Inc. (Nasdaq: VIRI) has reported its financial results for Q4 and the full year ended December 31, 2020, marking a significant operational period since its IPO in December 2020. The company is set to commence its Phase 2b fibromyalgia clinical trial (FORTRESS) in May 2021, with anticipated results by Q2 2022. Financial highlights include a net loss of $6.5 million for Q4 2020, up from $0.6 million in Q4 2019, and a full-year net loss of $10.3 million. The company maintains a cash position of $29.8 million, sufficient to support operations through 2022.
Virios Therapeutics (Nasdaq: VIRI) will report its fourth quarter and full year 2020 financial results on March 18, 2021, before the market opens. A conference call and webcast will be held on the same day at 8:30 a.m. ET for a corporate update. The company is focused on developing antiviral therapies for conditions linked to immune responses triggered by herpes simplex virus-1. Its lead candidate, IMC-1, has shown promise in Phase 2 trials and is currently in a Phase 2B trial with FDA fast track designation.
Virios Therapeutics (Nasdaq: VIRI), a clinical-stage biotechnology firm, announced that CEO Greg Duncan will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The focus will be on innovative treatments for fibromyalgia, highlighting their novel antiviral approach and the potential of their drug IMC-1, which has shown positive results in a Phase 2 trial. Following the presentation, a link for on-demand access will be available on Virios’ website. The company is committed to advancing treatments for conditions linked to virally maintained immune responses.
Virios Therapeutics (Nasdaq: VIRI) has announced a collaboration with Dr. Michael Camilleri from the Mayo Clinic to investigate antiviral therapy's effectiveness in managing Irritable Bowel Syndrome (IBS). The partnership aims to design a phase 2 proof-of-concept study targeting pain associated with IBS using IMC-1, a proprietary antiviral combination of famciclovir and celecoxib. This collaboration highlights the company's focus on advancing antiviral therapies for conditions linked to abnormal immune responses, including IBS and fibromyalgia.
Virios Therapeutics (Nasdaq: VIRI) announced its participation in the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. CEO Greg Duncan and CMO R. Michael Gendreau will provide a company overview. The presentation will be available for on-demand access starting January 11, 2021, at 6:00 AM ET on the company’s website. Virios Therapeutics focuses on developing novel antiviral therapies for diseases linked to abnormal immune responses, such as fibromyalgia, utilizing their lead candidate IMC-1, a combination of famciclovir and celecoxib.
Virios Therapeutics, Inc. (Nasdaq: VIRI) has successfully closed its IPO, issuing 3,450,000 shares of common stock at $10.00 each, raising gross proceeds of $34.5 million, including the full exercise of the underwriter’s option. ThinkEquity served as the sole book-running manager for this offering. The company focuses on developing antiviral therapies for diseases linked to abnormal immune responses triggered by viruses, with lead candidate IMC-1 targeting HSV-1 activation.
